Back to Newsroom

Vericel Reports Third-Quarter 2017 Financial Results

CAMBRIDGE, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) —  Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today reported financial results for the third quarter ended September 30, 2017.
READ MORE…